The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech ...

The deal terms make Roche responsible for manufacturing and supplying that engineered peptide, petrelintide. Once the new and expanded manufacturing capacity comes online, Roche said the company ...

Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning ...

Apple reported second-fiscal-quarter earnings Thursday that beat expectations. Amazon reported better-than-expected results ...

The two companies will jointly commercialise petrelintide in the United States and Europe, while Roche will obtain exclusive commercialisation rights in the rest of the world. The deal is expected ...

Last month, Roche in-licensed co-development and co-commercialization rights from Denmark’s Zealand Pharma for the latter’s long-acting amylin analog, petrelintide. The company plans to ...

Roche seeks US tariff relief in direct talks ... first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or obesity and type 2 diabetes.

The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

The obesity pipeline was strengthened with Zealand's amylin drug petrelintide. Roche is also awaiting key readouts this year for giredestrant (breast cancer) and fenebrutinib (multiple sclerosis).

Roche projected that its $50 billion manufacturing investment, to include R&D operations, will generate 1,000 jobs at the ...